Millipore Sigma Vibrant Logo

69825 NovaBlue Competent Cells - Novagen

View Products on Sigmaaldrich.com
69825
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
69825-4
Comprobando disponibilidad...
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Frasco de vidrio 1 ml
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      Solicitar precio
      Description
      OverviewNovaBlue is a K-12 strain ideally suited as an initial cloning host due to its high transformation efficiency, blue/white screening capability (with appropriate plasmids) and recA endA mutations, which result in high yields of excellent quality plasmid DNA. The DE3 lysogen of NovaBlue is potentially useful as a stringent host due to the presence of the lacIq repressor encoded by the F episome. Blue/white screening is not possible with NovaBlue(DE3) due to the presence of the lacZ α-peptide coding sequences in the lysogenic phage.
      This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




      This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
      Catalogue Number69825
      Brand Family Novagen®
      References
      Product Information
      Components
      Guaranteed efficiencyGuaranteed efficiency: > 1 x 10⁸ cfu/μg
      Quality LevelMQ100
      Applications
      Biological Information
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Multiple Toxicity Values, refer to MSDS
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      69825-4 04055977273991

      Documentation

      NovaBlue Competent Cells - Novagen Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      NovaBlue Competent Cells - Novagen Certificados de análisis

      CargoNúmero de lote
      69825

      Citas

      Título
    • Graham Christie, Milena Lazarevska and Christopher R. Lowe. (2008) Functional consequences of amino acid substitutions to GerVB, a component of the Bacillus megaterium spore germinant receptor. Journal of Bacteriology 190, 2014-2022.
    • Jennifer L. Farmer, et al. (2008) Galectin 15 (LGALS15) functions in trophectoderm migration and attachment. Federation of American Societies for Experimental Biology Journal 22, 548-560.
    • Brantley R. Herrin, et al. (2008) Structure and specificity of lamprey monoclonal antibodies. Procedings of the National Academy of Science 105, 2040-2045.
    • Samuel A. Shelburne, III, et al. (2008) A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Procedings of the National Academy of Science 105, 1698-1703.
    • Phillip J. Monaghan, David Leys and Nigel S. Scrutton. (2007) Mechanistic aspects and redox properties of hyperthermophilic L-proline dehydrogenase from Pyrococcus furiosus related to dimethylglycine dehydrogenase/oxidase. Federation of American Societies for Experimental Biology Journal 274, 2070-2087.
    • Xiuhua Pang and Susan T. Howard. (2007) Regulation of the α-crystallin gene acr2 by the mprAB two-component system of Mycobacterium tuberculosis. Journal of Bacteriology 189, 6213-6221.
    • Pernilla Larsson Birgander, et al. (2005) Nucleotide-dependent formation of catalytically competent dimers from engineered monomeric ribonucleotide reductase protein R1. Journal of Biological Chemistry 280, 14997-15003.
    • Catherine Paradis-Bleau, Francois Sanschagrin and Roger C. Levesque. (2005) Peptide inhibitors of the essential cell division protein FtsA. Protein Engineering Design and Selection 18, 85-91.
    • Francois Sanschagrin and Roger C. Levesque. (2005) A specific peptide inhibitor of the class B metallo-{beta}-lactamase L-1 from Stenotrophomonas maltophilia identified using phage display. Journal of Antimicrobial Chemotherapy 55, 252-255.
    • Laura I. Katona, et al. (2004) The Fur homologue in Borrelia burgdorferi. Journal of Bacteriology 186, 6443-6456.
    • Sharmila Sivendran, et al. (2004) Two novel mutant human adenylosuccinate lyases (ASLs) associated with autism and characterization of the equivalent mutant Bacillus subtilis ASL. Journal of Biological Chemistry 279, 53789-53797.
    • Deanne M. Compaan and W. Ross Ellington. (2003) Functional consequences of a gene duplication and fusion event in an arginine kinase. 206, 1545-1556.
    • Yusuf Kaya and James Ofengand. (2003) A novel unanticipated type of pseudouridine synthase with homologs in bacteria, archaea, and eukarya. RNA 9, 711-721.
    • Michael B. Murphy, et al. (2003) An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Research 31, e110-.
    • Ahmed El Zoeiby, et al. (2003) Identification of novel inhibitors of Pseudomonas aeruginosa MurC enzyme derived from phage-displayed peptide libraries. Journal of Antimicrobial Chemotherapy 51, 531-543.
    • Paul L. DeAngelis and Amy J. Padgett-McCue. (2000) Identification and molecular cloning of a chondroitin synthase from Pasteurella multocida type F. Journal of Biological Chemistry 275, 24124-24129.
    • In-Hong Choi, et al. (1997) Clonal expansion of CD8+ T cells in Kawasaki disease. Journal of Immunology 159, 481-486.
    • Thomas P. Shanley, et al. (1997) Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. Journal of Immunology 158, 3439-3448.
    • Y. Xu, et al. (1995) High-yield bacterial expressio, purification, and functional reconstitution of the tricarboxylate transport protein from rat liver mitochondria. Biochemical and Biophysical Research Communications 207, 783-789.
    • Protocolos de usuario

      Cargo
      TB009 Competent Cells